Billions of dollars are spent every year by pharma companies researching and testing new cancer treatments. Although there is a wealth of valuable, historical cancer clinical trial data, it’s not available. The Project Data Sphere initiative aims to change that because large pools of data can, and should, be put to use.
According to a new report from Tufts Center for the Study of Drug Development (Tufts CSDD), although many pharmaceutical companies are increasing the pace of new products by improving the efficiency of clinical trial operations, their medium- and long-term success will increasingly depend on their ability to support more efficient research and development (R&D) models.
Welcome to Grand Rounds: the Impact of Healthcare Reform.
For this edition of Grand Rounds, Vol. 7 No. 11, we’re focusing on the impact of healthcare reform: what are the changes to healthcare delivery, utilization, quality, costs (either as a provider or a patient) and outcomes. After all, these changes affect everyone, whether you’re a patient, a healthcare provider or a biomedical researcher.
A new U.S. Food and Drug Administration (FDA) docket was published on the FDA website last month. The draft guidance, when finalized, will represent the FDA’s current thinking on complementary and alternative medicine (CAM). Docket No. 2006D-0480: Draft Guidance for Industry on Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration  discusses when a CAM product is subject to the Federal Food, Drug, and Cosmetic Act (the Act) or the Public Health Service (PHS) Act.
Recently, an undercover pharmacy investigation conducted by 20/20 and reported on by Chief Investigative Correspondent Brian Ross evaluated prescription dispensing at some of the best known U.S. chain drug stores.
The results are surprising and the suggestions at the end of this article really could save your life or that of someone you love.